Yellow Fever Immune Response at Single Cell Resolution

Completed

Conditions studied: Healthy

In brief

The immune system is composed of diverse cell types with different functions that act together in order to defend against infection. This pilot study will test a new technology for studying these many different cell types at very large numbers at the level of individual cells. This method will then be used to identify the cell types and functions important for the immune response to the highly protective yellow fever vaccine, which will improve our understanding of effective vaccine features.

Key facts

Study ID

NCT03458780

Run by

Rockefeller University

People needed

6

Starts

2016-08-22

Expected to finish

2018-09-05

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female between the ages of 18 and 59 years old
• Volunteers who have not received a vaccination within 30 days of the YFV and do not anticipate to receive a vaccination within 30 days
• Volunteers who are seeking the YFV for either travel reasons or occupational risk
• Volunteers willing to undergo one screening visit, one visit to receive the YFV, and four post-vaccination visits
• Volunteers without medical conditions who are willing to give blood once for the development of the inDrop technique

You may not qualify if…

• Male or females under 18 or over 59 years of age
• Volunteers who received other vaccination less than 30 days prior to receiving the YFV
• Volunteers with acute or febrile disease
• Volunteers unable to return for the post vaccination follow-up visits
• Volunteers with an allergy to eggs, chicken proteins, gelatin, or other components of the Yellow Fever vaccine
• Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study
• Is pregnant or lactating
• Volunteers with a history of yellow fever vaccination and/or infection
• Volunteers with a history of viral hepatitis and/or non-viral liver disease
• In the opinion of the investigators, the volunteer is unlikely to comply with the study protocol
• Immunosuppressed individuals as a result of cancer, transplantation, and or primary immunodeficiency
• Immunosuppressed individuals as a result of medications (such as high-dose systemic corticosteroids, alkylating drugs, antimetabolites, TNF-α inhibitors (e.g., etanercept), IL-1 blocking agents (e.g., anakinra), and other monoclonal antibodies targeting immune cells (e.g.,rituximab, alemtuzumab) and/or radiation
• Volunteers with thymus disorders (including myasthenia gravis, Di George syndrome, or thymoma) and/or history of thymectomy
• Individuals infected with HIV

Where it is running

• The Rockefeller University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.